STF-083010

Cas No.:	307543-71-1
Chemical Name:	(E)-N-((2-hydroxynaphthalen-1-yl)methylene)thiophene-2-sulfonamide
Synonyms:	STF-083010,STF083010,STF 083010
SMILES:	O=C1C=CC2=CC=CC=C2/C/1=C\NS(C1=CC=CS1)(=O)=O
Formula:	C15H11NO3S2
M.Wt:	317.38
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	STF-083010 is an Ire1 inhibitor. STF-083010 inhibits Ire1 endonuclease activity, without affecting its kinase activity, after endoplasmic reticulum stress.
In Vivo:	Treatment with STF-083010 reduces the viability of HCT116 p53-/- cells by approximately 20% compared with that of HCT116 p53-/-cells. Administration of STF-083010 to tumors induced by HCT116 p53-/- cells significantly reduces tumor volume and weight by 75% and 73% at the endpoint, respectively[3].
In Vitro:	STF-083010 shows cytostatic and cytotoxic activity in a dose- and time-dependent manner. Treatment with STF-083010 shows significant antimyeloma activity in model human multiple myeloma (MM) xenografts. RPMI 8226 human MM cells grown as tumor xenografts are treated in NSG mice. Intraperitoneal injection of STF-083010 alone (day 1, day 8) significantly inhibits the growth of these tumors[1]. STF-083010 is an IRE1α-specific inhibitor. Four pancreatic cancer cell lines (Panc0403, Panc1005, BxPc3, MiaPaCa2) are treated with different combination of Bortezomib (10 or 50 nM) and STF (10 or 50 μM). The normalized isobologram analysis demonstrates synergistic activity between 10 μM STF and either 10 or 50 nM bortezomib in all four cell lines. Moreover, a higher concentration of STF (50 μM) attains synergy after addition of bortezomib either at a concentration of 10 nM when tested against BxPc3 cells, at a concentration of 50 nM against Panc1005 cells, and at either 10 or 50 nM against Panc0403 cells[2]. STF-083010 (50 μM) suppresses the growth of p53-deficient human cancer cells[3].